Wesley Hospital, Brisbane, Qld, Australia.
School of Medicine, University of Queensland, Brisbane, Qld, Australia.
BJU Int. 2020 Sep;126(3):396-401. doi: 10.1111/bju.15152. Epub 2020 Jul 28.
To determine the proportion of solitary rib lesions on pre-treatment Gallium-labelled prostate-specific membrane antigen (PSMA)/computed tomography (CT) scans in men with prostate cancer that are malignant and examine any predictive factors.
This retrospective single tertiary referral institution cohort study of men reviewed the results of Ga-PSMA-11 positron emission tomography (PET)/CT scans performed for primary staging prior to treatment of prostate cancer from July 2014 to September 2019. Men with PSMA uptake outside the prostate in only the rib lesion were included. A solitary rib lesion was considered to be malignant if it increased in size on follow-up imaging. A lesion was considered benign if the prostate-specific antigen (PSA) level remained <0.1 µg/L following a radical prostatectomy (RP), <2 µg/L above nadir following radiotherapy (RT) as per the Phoenix criteria, histology was benign on rib biopsy, or follow-up imaging showed no growth of the rib lesion. If a lesion did not meet these criteria it was considered indeterminate.
A total of 62 men had PSMA uptake in a solitary rib lesion; 54 went on to have RPs and eight underwent RT. In all, 61 of the men (98.4%) met the criteria for a benign rib lesion. Only one man had a false-negative malignant lesion. This man had a rib lesion with a low maximum standardised uptake value (SUV ) of 2.21 reported as benign, but the postoperative PSA level was 0.67 µg/L and the rib lesion progressed on follow-up imaging, with development of widespread metastases. Of the benign rib lesions, there were four false positives reported as possible metastases. Three had percutaneous rib biopsies, two of which came back with benign histology and one was indeterminate. The indeterminate biopsy patient had a RP and his postoperative PSA level was <0.1 µg/L. A total of 43 (69.4%) men with benign rib lesions had a SUV greater than the SUV of the malignant lesion.
To our knowledge, this is the first cohort study of men with PSMA-avid solitary rib lesions on pre-treatment Ga-PSMA PET/CT staging scans for prostate cancer. Our results indicate that the vast majority of these lesions have low-intensity uptake and are benign. Intervention to confirm this is not usually required.
确定在接受治疗前 Ga-前列腺特异性膜抗原(PSMA)/计算机断层扫描(CT)扫描中,前列腺癌患者孤立肋骨病变的比例,以及检查任何预测因素。
本回顾性单一三级转诊机构队列研究纳入了 2014 年 7 月至 2019 年 9 月期间,因前列腺癌接受治疗前 Ga-PSMA-11 正电子发射断层扫描(PET)/CT 扫描的男性。PSMA 摄取仅在肋骨病变中超出前列腺的男性被纳入研究。如果随访影像学显示肋骨病变增大,则孤立肋骨病变被认为是恶性的。如果前列腺特异性抗原(PSA)水平在根治性前列腺切除术后(RP)<0.1μg/L,放射治疗(RT)后 PSA 水平<2μg/L(基于 Phoenix 标准),肋骨活检显示组织学为良性,或随访影像学显示肋骨病变无生长,则认为病变为良性。如果病变不符合这些标准,则认为其为不确定。
共有 62 名男性的 PSMA 摄取在孤立肋骨病变中;54 名男性接受了 RP,8 名男性接受了 RT。总的来说,61 名男性(98.4%)符合良性肋骨病变的标准。只有一名男性出现了假阴性恶性病变。这名男性的肋骨病变最大标准化摄取值(SUV)为 2.21,报告为良性,但术后 PSA 水平为 0.67μg/L,且肋骨病变在随访影像学上进展,出现广泛转移。在良性肋骨病变中,有 4 例被报告为可能转移的假阳性。其中 3 例行经皮肋骨活检,其中 2 例组织学为良性,1 例为不确定。不确定活检患者行 RP 治疗,术后 PSA 水平<0.1μg/L。在 43 名(69.4%)良性肋骨病变患者中,SUV 大于恶性病变的 SUV。
据我们所知,这是首例在接受治疗前 Ga-PSMA PET/CT 分期扫描中,对前列腺癌患者的 PSMA 摄取孤立肋骨病变的男性进行的队列研究。我们的结果表明,这些病变绝大多数摄取强度低,为良性。通常不需要进行干预来确认这一点。